|
|
 |
|
Viewing report
|
|
|
|
Lead Optimization Strategies: Future Developments, Threats and Opportunities For Big Pharma, Specialty Pharma and Biotech
Business Insights, Sep 2005
The pharmaceutical industry has undergone considerable consolidation during the last 20 years as companies attempt to maintain double-digit sales growth and shareholder value. Strategic mergers and acquisitions have resulted in companies revitalizing their drug pipelines to replace blockbuster drugs that face patent expiration.
In many cases, whilst mergers cause a period of less productive transition, significant cost-savings can be reaped and overheads reduced. However, more and more companies are resorting to streamlining their internal programs, both pre-clinical and clinical, to improve productivity and the cost-effectiveness of bringing drugs to the market as well as in-licensing late-stage products and outsourcing screening programs which may be less economical to entertain in-house.
This report includes case studies of the following companies:
- AstraZeneca
- GlaxoSmithKline
- ArQule
- Locus Pharmaceuticals
|
|
|
|
